



(22) Date de dépôt/Filing Date: 1999/04/02
(41) Mise à la disp. pub./Open to Public Insp.: 1999/10/21
(62) Demande originale/Original Application: 2 321 157
(30) Priorité/Priority: 1998/04/09 (US60/081,231)

(51) Cl.Int./Int.Cl. *A61K 31/5375* (2006.01),
A61P 25/34 (2006.01)
(71) Demandeur/Applicant:
PHARMACIA & UPJOHN COMPANY, US
(72) Inventeurs/Inventors:
HASSAN, FRED, US;
MCCALL, JOHN MICHAEL, US;
TAYLOR, DUNCAN PAUL, US;
VON VOIGTLANDER, PHILIP F., US;
WONG, ERIK HO FONG, US
(74) Agent: MACRAE & CO.

(54) Titre : NOUVEAUX TRAITEMENTS POUR TROUBLES NERVEUX
(54) Title: NEW TREATMENTS FOR NERVOUS DISORDERS

(57) **Abrégé/Abstract:**

This patent application describes the treatment of Addictive Disorders, Psychoactive Substance Use Disorders, Intoxication disorders, Inhalation disorders, Alcohol addiction, Tobacco Addiction and or Nicotine Addiction; and Attention Deficit Hyperactivity Disorder (ADHD); comprising administering a therapeutically effective, nontoxic dose of Reboxetine and derivatives and or pharmaceutically acceptable salts thereof to a patient.



NEW TREATMENTS FOR NERVOUS DISORDERS

Abstract

This patent application describes the treatment of Addictive Disorders,
5 Psychoactive Substance Use Disorders, Intoxication disorders, Inhalation disorders,
Alcohol addiction, Tobacco Addiction and or Nicotine Addiction; and Attention Deficit
Hyperactivity Disorder (ADHD); comprising administering a therapeutically effective,
nontoxic dose of Reboxetine and derivatives and or pharmaceutically acceptable salts
thereof to a patient.

NEW TREATMENTS FOR NERVOUS DISORDERS

This application is a division of Canadian Patent Application Serial No. 2,321,157 filed April 2, 1999.

Field of the Invention

5 This invention describes new treatments for several nervous system disorders, including: Addictive Disorders, Psychoactive Substance Use Disorders, Nicotine Addiction or Tobacco Addiction resulting in Smoking Cessation and Attention Deficit Hyperactivity Disorder (ADHD). The treatment involves the administration of the drug Reboxetine to a patient in need.

Background

10 The introduction of tricyclic antidepressants in the early 1960s has provided a major advance in the treatment of neuropsychiatric disorders. Reactive and endogenous depressions, diagnoses formerly carrying grave prognostic implications, have become, with the introduction of the tricyclics, manageable disorders with a much smaller toll on the patient and the society as a whole. Electroconvulsive Shock Therapy once the only
15 efficacious treatment in spite of its highly invasive nature, has now become, thanks to tricyclics, an obsolete form of treatment in most Countries.

The early tricyclic compounds were reuptake inhibitors of all the catecholamines released in the synaptic cleft, thus resulting in prolongation and enhancement of the
20 dopamine (DA), noradrenaline (NA) and serotonin (5-hydroxytryptamine = 5-HT) action. Desipramine, for example, has been characterized as "one of the most studied of the tricyclic anti-depressants in ADHD children and adolescents." T. E. Wilens, et al. *Am. J. Psychiatry* 153:1147-1153, 1148 (1996). It has also been considered as a treatment for the disease in adults. *Id.* Unfortunately, a lack of selectivity for most tricyclics, including
25 desipramine can also cause undesired side effects particularly on the acetylcholine (especially the muscarinic component), and histamine mediated neurotransmission.

Because of these unwanted pharmacodynamic activities, cognitive impairment, sedation, urinary and gastrointestinal tract disturbances, increased intraocular pressure were limiting factors in the clinical use of these compounds and often required discontinuation of
30 treatment. Of utmost concern were also the cardiac toxic effects and the proconvulsant activity of this group of drugs.

Another drug, methylphenidate, is also known to have clinical efficacy for the treatment of ADHD. Wender, P.H., et al. *Am. J. Psychiatry* 142:547-552 (1985).

More recently, selective reuptake inhibitors for serotonin (SSRI) have been introduced with definite advantages in regard to fewer side effects without loss of efficacy.

Here we present the surprising finding that one particular drug from a new category of antidepressants, a so called noradrenaline (NA) reuptake inhibitor can be used to manage or treat a few special diseases, diseases having symptoms outside of what are usually considered depression symptoms. Now these diseases may be treated with Reboxetine.

Summary of the Invention

This patent application describes the treatment of Addictive Disorders, Psychoactive Substance Use Disorders, Nicotine Addition or Tobacco Addiction (with a result of Smoking Cessation or a decrease in smoking) and Attention Deficit Hyperactivity Disorder (ADHD), comprising administering a therapeutically effective, nontoxic dose of Reboxetine and derivatives and or pharmaceutically acceptable salts thereof to a patient.

Reboxetine is the generic name of the pharmaceutical substance with the chemical name of 2-(1-((2-ethoxyphenoxy)benzyl)-morpholine, and its pharmaceutically acceptable salts. Reboxetine can be a free base, or it can include reboxetine methanesulfonate (also called reboxetine mesylate) or any other pharmaceutically acceptable salt that does not significantly affect the pharmaceutical activity of the substance.

A preferred dose range is 4 to 10 mg per patient per day and the most preferred dose is 6 to 8 mg or 8 to 10 mg per patient daily, depending upon the patient, delivered twice a day (b.i.d.).

Additional Description of the Invention and Description of the Preferred Embodiment(s)

Reboxetine is the generic name of the pharmaceutical substance with the chemical name of 2-(1-((2-ethoxyphenoxy)benzyl)-morpholine, and its pharmaceutically acceptable salts. Reboxetine can be a free base, or it can include reboxetine methanesulfonate (also called reboxetine mesylate) or any other pharmaceutically acceptable salt that does not significantly affect the pharmaceutical activity of the substance. Reboxetine and a method of synthesis are described in U.S. 4,229,449, issued 21 Oct. 1980, Melloni et. al., methods of preparation are described in US 5,068,433, issued 26 Nov. 1991, Melloni et al. and in US 5,391,735, issued 21 Feb. 1995. Reboxetine may also be known under the trade name of EDRONAX™.

The pharmaceutical compositions and methods of administration are described in US 4,229,449 at col. 18, lines 33-66. Twice a day dosing is preferred with current formulations.

Reboxetine acts as an antidepressant. Antidepressants are frequently grouped into categories or "generations." The first generation of antidepressants were usually tricyclic antidepressants such as maprotiline that affected various neurotransmitter systems and are associated with many undesirable side effects. The second generation of antidepressants, such as mianserine, mirtrazapine and trazodone are largely devoid of anticholinergic action and their adrenergic and antihistaminic effects are weaker. These are contrasted with the third generation of antidepressants (e.g. SSRI, ipsapirone, viloxazine, reboxetine, bupropione) that mediate only one of the three main neurotransmitter system for depression (5-HT, noradrenaline, dopamine) and they do not affect muscarine, histamine and adrenergic cerebral systems. Svestka, J. "Antidepressives of the 3rd, 4th and 5th generation," *Cesk-Psychiatr.* 1994 Feb; 90(1):3-19. (Czech).

Reboxetine however; does not act like most antidepressants. Unlike tricyclic antidepressants and even selective serotonin reuptake inhibitors (SSRIs), reboxetine is ineffective in the 8-OH-DPAT hypothermia test, indicating that reboxetine is not a selective serotonin reuptake inhibitor rather it is selective for the noradrenergic system. Thus, reboxetine is not an SSRI, rather it is considered a novel, selective, noradrenaline-reuptake inhibitor (NARI). Leonard-BE, "Noradrenaline in basic models of depression." *European-Neuropsychopharmacol.* 1997 Apr; 7 Suppl 1: S11-6; discussion S71-3. Unlike most drugs, Reboxetine is a highly selective norepinephrine uptake inhibitor, with only marginal serotonin and no dopamine uptake inhibitory activity. The compound displays only weak or no anti-cholinergic activity in different animal models and is devoid of monoamine oxidase (MAO) inhibitory activity.

Reboxetine is highly potent and fast acting. Our investigations indicate Reboxetine has potent antireserpine activity and combines the inhibitory properties of classical tricyclic antidepressants on the reuptake of noradrenaline with an ability to desensitize J-adrenergic receptor function without showing any appreciable interaction with muscarinic cholinergic and I-adrenergic receptors. Moreover, Reboxetine shows less vagolytic activity than other tricyclic antidepressants.

The inventors have discovered that, because of its unique properties, Reboxetine has been found particularly useful for treating or enhancing the treatment of a few psychiatric

symptoms or disorders, with greater efficacy and with fewer side effects, than are treated by known drugs. Furthermore, the inventors here have also discovered that Reboxetine can also be used to treat or to enhance the treatment of a few other specific psychiatric symptoms or disorders. The symptoms or disorders amenable to treatment with Reboxetine are provided below.

The dosage used to treat all of the disorders described here is as follows. Reboxetine is well tolerated and has a wide safety range, it can be administered in a dose range of active ingredient from about 1 to over 20 mg/kg. It is more commonly provided in dosages of from 1 to 20 mg per patient per day. The compound may be administered by any suitable method including a convenient oral dosage form. A preferred method is oral dosing twice a day. The preferred dose range is 4 to 10 mg per patient per day and the most preferred dose is 6 to 8 mg or 8 to 10 mg per patient daily, depending upon the patient, delivered twice a day (b.i.d.). It can also be given at dosages of 2, 4, 6, 8, 10 or 12 mg per patient per day or fractions thereof: For example, suitable administrations could be 4 mg in the morning and 2 or 4 mg in the evening or 6 mg in the morning and 4 mg in the evening. In some patients the ideal dosing would be 3-5 mg in the morning and 3-5 mg in the evening. A skilled practitioner would be expected to determine the precise level of dosing. The ideal dosing would be routinely determined by an evaluation of clinical trials and the needs of the patient.

The diseases described for treatment here are:

I. Addictive Disorders and Psychoactive Substance Use Disorders, such as Intoxication disorders, Inhalation disorders, Alcohol addiction, Tobacco Addiction and or Nicotine Addiction. Tobacco and Nicotine addiction would be treated with the goal of achieving either Smoking Cessation or Smoking Reductions.

Addictive Disorders, Alcohol and Other Psychoactive Substance Use Disorders, disorders related to Intoxication and Inhalants and especially Tobacco Addiction or Nicotine Addiction, may be treated with Reboxetine. Tobacco Addiction or Nicotine Addiction would be treated with Reboxetine in order to achieve smoking/chewing cessation or smoking/chewing reduction. General descriptions of Addictive Disorders, including disorders related to Intoxication and Inhalants and Tobacco Addiction or Nicotine Addiction may be found in many standard sources, such as, The American Psychiatric Press Textbook of Psychiatry, Second Edition, Edited by Robert E. Hales, Stuart C. Yudofsky, and John A. Talbott, copyright 1994, especially pp. 401 et. seq.,

section on "Nicotine". Another of many texts is the Manual of Psychiatric Therapeutics, Second Edition, edited by Richard I. Shader, especially pp. 85 from Chapter 11 (Hypnosis).

The treatment of Alcohol and Other Psychoactive Substance Use Disorders, such as disorders related to Intoxication and Inhalants and Tobacco Addiction or Nicotine Addiction but especially Tobacco Addiction involves the administration of Reboxetine in a manner and form that provide a reduction in the symptoms of the disease. Tobacco Addiction or Nicotine Addiction in particular would be treated to achieve a reduction or cessation of smoking or chewing of nicotine containing materials by a patient. Cessation or a reduction in smoking or chewing of addictive or psychoactive substances involves the administration of Reboxetine in a manner and form that provide a reduction in the symptoms of the disease, or with Tobacco or Nicotine with a reduction in the amount smoked or chewed.. See the general description above for administration of Reboxetine.

II. Attention Deficit Hyperactivity Disorder (ADHD).

ADHD is a condition or disease state that may be treated with Reboxetine. General descriptions of ADHD, may be found in many standard sources, such as, The American Psychiatric Press Textbook of Psychiatry, Second Edition, Edited by Robert E. Hales, Stuart C. Yudofsky, and John A. Talbott, copyright 1994, especially pp. 741 et al., section on "ADHD". Another of many texts is the Manual of Psychiatric Therapeutics, Second Edition, edited by Richard I. Shader, especially Chapter 18, Attention-Deficit Hyperactivity Disorder, and pp. 172 et. seq.

The treatment of Attention Deficit Hyperactivity Disorder in children and adults involves the administration of Reboxetine in a manner and form that provide a reduction in the symptoms of the disease. In particular, Reboxetine or a pharmaceutically acceptable salt thereof may be used to increase the attention span and calm individuals afflicted with ADHD. A child or young adult may require a smaller dosage depending upon the size, age, condition of the patient. See general description above for administration of Reboxetine.

CLAIMS:

1. The use of reboxetine, or its derivatives, or pharmaceutically acceptable salts thereof in the manufacture of a medicament for treating or enhancing the treatment of a disorder selected from addictive disorders, psychoactive substance use disorders, intoxication disorders, inhalation disorders, alcohol addiction, tobacco addiction and nicotine addiction.
5
2. The use of claim 1, wherein the compound is reboxetine.
3. The use of claim 2, wherein the medicament is to treat or enhance the treatment of tobacco and / or nicotine addiction.
4. The use of claim 3, wherein the medicament is to reduce the craving for tobacco or nicotine containing products.
10
5. The use of claim 3, wherein the medicament is to reduce the smoking or chewing of tobacco or nicotine containing products.
6. The use of any of claims 2 to 5 wherein the reboxetine dose range is 4 to 10 mg per patient per day.
- 15 7. The use of claim 6, wherein the reboxetine dose range is 6 to 8 mg per patient per day.